DURECT: FDA OKs POSIMIR® For Post-Surgical Pain

 POSIMIR is the only approved sustained-release bupivacaine product indicated for up to 72 hours of post-surgical analgesia from a single application

Conference Call Today, February 2, 2021 at 4:30pm ET

The DURECT management team will host a conference call to discuss the contents of this press release today at 4:30pm ET / 1:30pm PT:

Toll Free: 877-407-0784
International: 201-689-8560
Conference ID: 13716187
Webcast: http://public.viavid.com/index.php?id=143426

The conference call will also be available by webcast on DURECT's homepage at www.durect.com under the "Investors" tab.  If you are unable to participate during the webcast, the call will be archived on DURECT's website under "Event Calendar" in the "Investors" section.

https://investors.durect.com/news-releases/news-release-details/durect-corporation-announces-us-fda-approval-posimirr-post